Annual CFO
-$21.05 M
-$7.50 M-55.34%
31 December 2023
Summary:
Context Therapeutics annual cash flow from operations is currently -$21.05 million, with the most recent change of -$7.50 million (-55.34%) on 31 December 2023. During the last 3 years, it has fallen by -$20.01 million (-1934.37%). CNTX annual CFO is now -1934.37% below its all-time high of -$1.03 million, reached on 31 December 2020.CNTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$1.93 M
+$1.42 M+42.39%
01 September 2024
Summary:
Context Therapeutics quarterly cash flow from operations is currently -$1.93 million, with the most recent change of +$1.42 million (+42.39%) on 01 September 2024. Over the past year, it has increased by +$1.53 million (+44.14%). CNTX quarterly CFO is now -4334.17% below its all-time high of -$43.60 thousand, reached on 30 September 2021.CNTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$16.88 M
+$1.53 M+8.30%
01 September 2024
Summary:
Context Therapeutics TTM cash flow from operations is currently -$16.88 million, with the most recent change of +$1.53 million (+8.30%) on 01 September 2024. Over the past year, it has increased by +$873.30 thousand (+4.92%). CNTX TTM CFO is now -8905.82% below its all-time high of -$187.40 thousand, reached on 31 March 2020.CNTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CNTX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -55.3% | +44.1% | +4.9% |
| 3 y3 years | -1934.4% | -4334.2% | -320.5% |
| 5 y5 years | - | - | - |
CNTX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -1934.4% | at low | -4334.2% | +73.3% | -320.5% | +19.8% |
| 5 y | 5 years | -1934.4% | at low | -4334.2% | +73.3% | -8905.8% | +19.8% |
| alltime | all time | -1934.4% | at low | -4334.2% | +73.3% | -8905.8% | +19.8% |
Context Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.93 M(-42.4%) | -$16.88 M(-8.3%) |
| June 2024 | - | -$3.36 M(-23.0%) | -$18.40 M(-6.5%) |
| Mar 2024 | - | -$4.36 M(-39.7%) | -$19.68 M(-6.5%) |
| Dec 2023 | -$21.05 M(+55.3%) | -$7.23 M(+108.8%) | -$21.05 M(+18.6%) |
| Sept 2023 | - | -$3.46 M(-25.3%) | -$17.75 M(+2.7%) |
| June 2023 | - | -$4.63 M(-19.2%) | -$17.28 M(+11.8%) |
| Mar 2023 | - | -$5.73 M(+45.8%) | -$15.46 M(+14.1%) |
| Dec 2022 | -$13.55 M | -$3.93 M(+31.2%) | -$13.55 M(-7.1%) |
| Sept 2022 | - | -$2.99 M(+6.7%) | -$14.58 M(+25.4%) |
| June 2022 | - | -$2.81 M(-26.6%) | -$11.63 M(+6.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$3.82 M(-23.0%) | -$10.90 M(+23.9%) |
| Dec 2021 | -$8.80 M(+750.5%) | -$4.96 M(>+9900.0%) | -$8.80 M(+119.2%) |
| Sept 2021 | - | -$43.60 K(-97.9%) | -$4.01 M(-7.1%) |
| June 2021 | - | -$2.08 M(+21.2%) | -$4.32 M(+68.6%) |
| Mar 2021 | - | -$1.72 M(+874.6%) | -$2.56 M(+147.7%) |
| Dec 2020 | -$1.03 M(-63.5%) | -$176.00 K(-49.7%) | -$1.03 M(+20.5%) |
| Sept 2020 | - | -$350.20 K(+9.1%) | -$858.60 K(+68.9%) |
| June 2020 | - | -$321.00 K(+71.3%) | -$508.40 K(+171.3%) |
| Mar 2020 | - | -$187.40 K | -$187.40 K |
| Dec 2019 | -$2.84 M | - | - |
FAQ
- What is Context Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Context Therapeutics?
- What is Context Therapeutics annual CFO year-on-year change?
- What is Context Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Context Therapeutics?
- What is Context Therapeutics quarterly CFO year-on-year change?
- What is Context Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Context Therapeutics?
- What is Context Therapeutics TTM CFO year-on-year change?
What is Context Therapeutics annual cash flow from operations?
The current annual CFO of CNTX is -$21.05 M
What is the all time high annual CFO for Context Therapeutics?
Context Therapeutics all-time high annual cash flow from operations is -$1.03 M
What is Context Therapeutics annual CFO year-on-year change?
Over the past year, CNTX annual cash flow from operations has changed by -$7.50 M (-55.34%)
What is Context Therapeutics quarterly cash flow from operations?
The current quarterly CFO of CNTX is -$1.93 M
What is the all time high quarterly CFO for Context Therapeutics?
Context Therapeutics all-time high quarterly cash flow from operations is -$43.60 K
What is Context Therapeutics quarterly CFO year-on-year change?
Over the past year, CNTX quarterly cash flow from operations has changed by +$1.53 M (+44.14%)
What is Context Therapeutics TTM cash flow from operations?
The current TTM CFO of CNTX is -$16.88 M
What is the all time high TTM CFO for Context Therapeutics?
Context Therapeutics all-time high TTM cash flow from operations is -$187.40 K
What is Context Therapeutics TTM CFO year-on-year change?
Over the past year, CNTX TTM cash flow from operations has changed by +$873.30 K (+4.92%)